Changes in brain function of depressed subjects during treatment with placebo

American Journal of Psychiatry

Volumn 159, Issue 1, 2002, Pages 122-129

  Leuchter, Andrew F ^a   Cook, Ian A ^b   Witte, Elise A ^b   Morgan, Melinda ^b   Abrams, Michelle ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE;

ARTICLE; BRAIN FUNCTION; BRAIN PERFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; ADULT; BRAIN CORTEX; COMPARATIVE STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

ADULT; CEREBRAL CORTEX; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT;

EID: 0036356299     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.1.122     Document Type: Article

References (32)

1. Shapiro AK, Shapiro E: The Powerful Placebo: From Ancient Priest to Modern Physician. Baltimore, Johns Hopkins University Press, 1997
2. Quitkin FM: Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry 1999; 156:829-836
3. Kirsch I, Sapirstein G: Listening to Prozac and hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment article 2a, posted July 28, 1998. http://journals.apa.org/prevention/volume1/pre0010002a. html
4. Kirsch I: Specifying nonspecific: psychological mechanisms of placebo effects, in The Placebo Effect: An Interdisciplinary Exploration. Edited by Harrington A. Cambridge, Mass, Harvard University Press, 1999, pp 166-186
5. Enserlink M: Psychopharmacology: can the placebo be the cure? Science 1999; 284:238-240
6. Quitkin FM, Stewart JW, McGrath PJ: Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993; 163:30-34
7. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava MD, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P: Use of pattern analysis to predict differential relapse of remitted patients with major depression during one year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55:334-343
8. Drevets WC, Raichle ME: Neuroanatomical circuits in depression: implications for treatment mechanisms. Psychopharmacol Bull 1992; 28:261-274
9. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386:824-827
10. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang S-C, Wu H-M, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR: Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001; 58:631-640
11. Nobler MS, Sackeim HA, Prohovnik I: Regional cerebral blood flow in mood disorders, III: treatment and clinical response. Arch Gen Psychiatry 1994; 51:884-897
12. Nobler MS, Sackeim HA, Louie J, Prohovnik I, Roose SP, Van Heertum R: Clinical response to antidepressants is associated with reduced frontal CBF in late-life depression, in 1998 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1998, p 168
13. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M: Relationship between brain activity and cortical perfusion in normal subjects. Psychiatry Res Neuroimaging 1999; 90: 125-140
14. Cook IA, Leuchter AF, Uijtdehaage SHJ, Osato S, Holschneider DH, Abrams M, Rosenberg-Thompson S: Altered cerebral energy utilization in late life depression. J Affect Disord 1998; 49: 89-99
15. Leuchter AF, Cook IA, Uijtdehaage SHJ, Lufkin RB, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S, O'Hara R, Simon SL, Babaie AB: Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry 1997; 58(suppl 16):22-31
16. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
17. Cook IA, Leuchter AF, Witte E, Abrams M, Uijtdehaage SHJ, Stubbeman W, Rosenberg-Thompson S, Anderson-Hanley C: Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res 1999; 85:263-273
18. Cook IA, O'Hara R, Uijtdehaage S, Mandelkern M, Leuchter AF: Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr Clin Neurophysiol 1998; 107:404-414
19. Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA: Changes in brain functional connectivity in Alzheimer's-type and infarct dementia. Brain 1992; 115:1543-1561
20. Brenner RP, Ulrich RF, Reynolds CF: EEG spectral findings in healthy elderly men and women: sex differences. Electroencephalogr Clin Neurophysiol 1995; 94:1-5
21. Ulrich G, Haug HJ, Fahndrich E: Acute versus chronic EEG effects in maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord 1994; 32:213-217
22. Ulrich G, Renfordt E, Zeller G, Frick K: Interrelation between change in the EEG and psychopathology under pharmacotherapy for endogenous depression: a contribution to the predictor question. Pharmacopsychiatry 1984; 17:178-183
23. Baxter LR, Phelps ME, Mazziotta JC: Cerebral metabolic rates for glucose in mood disorders: studies with positron emission tomography and fluorodeoxyglucose F18. Arch Gen Psychiatry 1985; 42:441-447
24. Sackeim HA, Prohovnik I: Brain imaging studies of depressive disorders, in The Biology of Depressive Disorders, Part A: A Systems Perspective. Edited by Mann JJ, Kupfer DJ. New York, Plenum, 1993, pp 205-258
25. Wilcox C, Cohn J, Linden R, Heiser J, Lucas P, Morgan DL, De-Francisco D: Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull 1992; 28:157-162
26. Khan A, Brown WA: Who should receive antidepressants: suggestions from placebo treatment. Psychopharmacol Bull 1991; 27:271-274
27. Quitkin FM, Rabkin JG, McGrath PJ, Stewart JW, Harrison W, Ross DC, Tricamo E, Fleiss J, Markowitz J, Klein DF: Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 1991; 148:193-196
28. Quitkin FM, McGrath PJ, Rabkin JG, Stewart JW, Harrison W, Ross DC, Tricamo E, Fleiss J, Markowitz J, Klein DF: Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991; 148:197-203
29. Quitkin FM, McGrath PJ, Stewart JW, Ocepek-Welikson K, Taylor BP, Nunes E, Delivannides D, Agosti V, Donovan SJ, Ross D, Petkova E, Klein DF: Placebo run-in period in studies of depressive disorders. Br J Psychiatry 1998; 173:242-248
30. Ribeiro SC, Tandon R, Grunhaus L, Greden JF: The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993; 150:1618-1629
31. Sonawalla SB, Renshaw PF, Moore CM, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M: Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry 1999; 156: 1638-1640
32. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? an analysis of clinical trials comparing placebo treatment with no treatment. N Engl J Med 2001; 344:1594-1602; correction, 345:304